TSHA gains institutional backing as Morgan Stanley files amended 13G

Rhea-AI Filing Summary

Morgan Stanley and subsidiary Morgan Stanley Capital Services LLC filed Amendment No. 1 to Schedule 13G reporting a passive stake in Taysha Gene Therapies, Inc. (TSHA) as of 30 Jun 2025.

The filing discloses 16,858,644 common shares, equal to 6.7 % of the outstanding class (CUSIP 877619106). Voting and dispositive authority are entirely shared: 16,651,747 shares with shared voting power and 16,858,644 shares with shared dispositive power; neither entity claims sole authority. Morgan Stanley is classified as a holding company/control person, while Morgan Stanley Capital Services LLC is a broker-dealer. The securities are held in the ordinary course of business with no intent to influence control of the issuer.

Positive

• Morgan Stanley’s disclosure of a 6.7 % stake (16.86 M shares) introduces notable institutional ownership that could improve liquidity and investor confidence.

Negative

• None.

Insights

Financial Analyst

TL;DR — Morgan Stanley’s 6.7 % passive stake signals growing institutional support for TSHA but does not alter governance.

The amended 13G confirms that Morgan Stanley collectively controls 16.9 M TSHA shares, giving the bank visibility into the company’s progress while remaining a non-activist holder. Institutional ownership at this level can tighten the float, improve liquidity and potentially enhance market confidence in the biotech’s capital-raising prospects. Because all power is shared and the filing cites ordinary-course motives, the disclosure is considered passive, lowering the probability of near-term strategic pressure on management.

Risk Analyst

TL;DR — Ownership is material but passive; limited immediate governance or risk ramifications.

The 13G shows no sole voting or dispositive power, so control risk remains minimal. A single institution holding 6.7 % marginally raises concentration risk yet stays below the 10 % threshold that could trigger heightened regulatory scrutiny. Overall impact is neutral on risk metrics.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Taysha Gene Therapies, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

877619106

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 877619106

1

Names of Reporting Persons

Morgan Stanley

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 16,651,747.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 16,858,644.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

16,858,644.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.7 %

12

Type of Reporting Person (See Instructions)

HC, CO

SCHEDULE 13G

CUSIP No. 877619106

1

Names of Reporting Persons

Morgan Stanley Capital Services LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 14,095,143.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 14,095,143.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

14,095,143.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.6 %

12

Type of Reporting Person (See Instructions)

BD, CO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Taysha Gene Therapies, Inc.
(b)	Address of issuer's principal executive offices: 3000 PEGASUS PARK DRIVE, SUITE 1430, DALLAS, TX, 75247
Item 2.
(a)	Name of person filing: 1: Morgan Stanley 2: Morgan Stanley Capital Services LLC
(b)	Address or principal business office or, if none, residence: 1: 1585 Broadway, New York, NY 10036 ;2: 1585 Broadway, New York, NY 10036
(c)	Citizenship: 1: Delaware 2: Delaware
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 877619106
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See the response(s) to Item 9 on the attached cover page(s).
(b)	Percent of class: 6.7 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See the response(s) to Item 5 on the attached cover page(s).
	(ii) Shared power to vote or to direct the vote: See the response(s) to Item 6 on the attached cover page(s).
	(iii) Sole power to dispose or to direct the disposition of: See the response(s) to Item 7 on the attached cover page(s).
	(iv) Shared power to dispose or to direct the disposition of: See the response(s) to Item 8 on the attached cover page(s).
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See Exhibit 99.2
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. * In Accordance with the Securities and Exchange Commission Release No. 34-39538 (January 12, 1998) (the "Release"), this filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by certain operating units (collectively, the "MS Reporting Units") of Morgan Stanley and its subsidiaries and affiliates (collectively, "MS"). This filing does not reflect securities, if any, beneficially owned by any operating units of MS whose ownership of securities is disaggregated from that of the MS Reporting Units in accordance with the Release.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Morgan Stanley

Signature:	Christopher O'Hara
Name/Title:	Authorized Signatory, Morgan Stanley
Date:	08/06/2025

Morgan Stanley Capital Services LLC

Signature:	Christopher O'Hara
Name/Title:	Authorized Signatory, Morgan Stanley Capital Services LLC
Date:	08/06/2025

Exhibit Information

EXHIBIT NO. EXHIBITS ------------------ ------------------------------------ 99.1 Joint Filing Agreement 99.2 Item 7 Information * Attention. Intentional misstatements or omissions of fact constitute federal criminal violations (see 18 U.S.C. 1001).

FAQ

How many Taysha Gene Therapies (TSHA) shares does Morgan Stanley report owning?

The Schedule 13G/A states Morgan Stanley beneficially owns 16,858,644 common shares.

What percentage of TSHA’s outstanding stock does this represent?

The filing lists ownership of 6.7 % of the company’s common shares.

Does Morgan Stanley have sole voting or dispositive power over TSHA shares?

No. The firm reports 0 shares with sole voting/dispositive power; all authority is shared.

What is the event date covered by this Schedule 13G/A?

The beneficial ownership information is as of 30 June 2025.

Is Morgan Stanley’s position classified as passive or activist?

The filing states the shares are held in the ordinary course of business, indicating a passive investment.